F6T Stock Chart & Stats
€2.11
-€0.03(-1.29%)
At close: 4:00 PM EDT
€2.11
-€0.03(-1.29%)
Day’s Range― - ―
52-Week Range€0.79 - €2.67
Previous CloseN/A
Volume0.00
Average Volume (3M)128.00
Market Cap
€222.96M
Enterprise Value€246.98M
Total Cash (Recent Filing)€153.77M
Total Debt (Recent Filing)€75.67M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Oct 29, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding119,820,510
10 Day Avg. Volume164
30 Day Avg. Volume128
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)17.56
P/FCF Ratio-1.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.96Price Target Upside182.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.95
Revenue Forecast (FY)€4.98M
Bulls Say, Bears Say
Bulls Say
Off-the-shelf Cell Therapy PlatformFate’s proprietary iPSC-derived platform is designed to produce standardized, allogeneic immune-cell therapies rather than relying solely on individualized manufacturing. If execution remains successful, this approach could broaden treatment access, support repeatable development across programs, and create durable platform value.
Non-dilutive Clinical FundingThe $15 million CIRM grant provides non-dilutive support for a potentially registrational Phase 2 trial, reducing the immediate funding burden on Fate. External backing also validates the program’s relevance and can help preserve capital for advancing FT819 through important clinical milestones.
Regulatory And Clinical MomentumFT819’s RMAT designation, FDA CMC readiness participation, and encouraging early clinical findings indicate progress across regulatory, manufacturing, and clinical dimensions. Together, these elements may improve development efficiency and strengthen the program’s potential position in autoimmune cell therapy.
Bears Say
No Recurring Product RevenueFate remains dependent on collaboration, licensing, reimbursement, milestone, and financing sources because it has no established recurring revenue from approved products. This makes the business model less predictable and leaves future financial capacity dependent on development progress and external funding.
Persistent Cash BurnPersistent operating and free-cash-flow deficits show that Fate’s current activities consume substantial cash rather than funding themselves. Continued burn can force additional financing before products generate revenue, increasing dilution risk and potentially restricting the pace or scope of clinical investment.
Shrinking Equity Base And LossesMaterial erosion of the equity base, combined with negative gross profit and large operating losses, indicates that Fate is consuming shareholder capital without yet demonstrating sustainable economic returns. This weakens financial flexibility and makes future execution more sensitive to financing needs.
Fate Therapeutics News
F6T FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was €0.79 and its highest was €2.67 in the past 12 months.
What is Fate Therapeutics’s market cap?
Fate Therapeutics’s market cap is €222.96M.
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is today.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Aug 13, 2026. The company reported -€0.224 earnings per share for the quarter, beating the consensus estimate of -€0.239 by €0.015.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -0.24.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 119,820,510 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -€0.224 in its last earnings report, beating expectations of -€0.239. Following the earnings report the stock price went down -0.782%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Currently, no hedge funds are holding shares in DE:F6T
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fate Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€5.96 (182.24% Upside)
€5.96 (182.24% Upside)
Blogger Sentiment
Neutral
DE:F6T Sentiment 50%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth €181.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.54%
12-Months-Change
Fundamentals
Return on Equity
-65.08%
Trailing 12-Months
Asset Growth
-30.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Fate Therapeutics
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
F6T Stock 12 Month Forecast
Average Price Target
€5.96
▲(182.24% Upside)